ACRS
NASDAQ HealthcareAclaris Therapeutics, Inc. - Common Stock
Biotechnology
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
�� 市场数据
| 价格 | $5.36 |
|---|---|
| 成交量 | 2,063,079 |
| 市值 | 748.60M |
| 贝塔系数 | 0.770 |
| RSI（14日） | 62.2 |
| 200日均线 | $3.54 |
| 50日均线 | $4.82 |
| 52周最高 | $5.85 |
| 52周最低 | $1.46 |
| Forward P/E | -6.47 |
| Price / Book | 5.21 |
🎯 投资策略评分
ACRS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (65/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🔪 Falling Knife (6/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ACRS in your text
粘贴任何文章、记录或帖子 — 工具将提取 ACRS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.